Building a National Research Network via Clinical and Translational Science Awards

Hepatitis C Therapeutic Registry and Research Network

ClinicalTrials.gov Identifier: NCT01474811

UF Clinical and Translational Science Institute
UNIVERSITY of FLORIDA

UNC SCHOOL OF MEDICINE

National CTSA Research Network

- **Mission**: to establish a nationwide registry of patients undergoing treatment with new therapies for HCV at both academic and community practices
- **Specific aims**
  - Improve information of populations underrepresented in phase III trials
  - Identify and remediate educational gaps and adverse event management
  - Serve as a core for collaborative, translational studies
- **Structure**
  - Chairs:
    - Nelson (UF) : clinical coordinating center and biorepository
    - Fried (UNC): data coordinating center (REDCap-based)
  - Trial network: 25 CTSA institutions and associated community engagement outreach; centralized data collection service
- **Highlights**
  - Partnership: academia + industry + FDA
  - Funding: $12 million
  - > 1,100 pts enrolled to date (approx 200/month)

HCV TARGET

HCV TARGET Organizational Chart



HCV TARGET

Building a National Consortium



HCV TARGET

HCV-TARGET
Phase I

- Longitudinal, observational study
  - Prospective and sequential, retrospective cohorts enrolling
- Inclusion criteria:
  - Adult patients (≥ 18 years) being treated with or who have been treated with antiviral regimens that contain telaprevir or boceprevir
- Exclusion criteria:
  - Inability to provide written informed consent unless waiver of informed consent granted by local IRB
- Biorepository: baseline DNA and serum at key timepoints
  - Baseline, week 2, 4/8, 12/16, EOT (protocol or breakthrough/relapse), follow-up SVR (12 or 24)

HCV TARGET

Primary Specific Aims

- Safety and efficacy in populations represented and underrepresented in phase III clinical trials
  - African Americans / Hispanics, cirrhosis, null responders, age > 65
  - Subgroup analyses to determine the cumulative influence of IL28B, fibrosis, viral subtype (1a vs 1b), other co-morbidities
- To refine point estimates and narrow confidence intervals
- Adverse event surveillance and management
  - Anemia, rash, anorectal, dysgeusia, etc
- Virologic breakthrough and resistance
  - Biorepository sample collection
- Impact of viral load measurement on treatment efficacy
  - Compliance / utility of current futility rules
  - Clinical relevance of “detectable / BLOQ” vs “undetectable”
- Evaluate/inform FDA pharmacometric modeling
  - Unstudied populations and dosing regimens

HCV-TARGET

Commitment to Highest Quality Data and Samples

- Utilizing CTSA Consortium REDCap data management software
  - Includes standard features of advanced clinical research data management systems:
    - Custom design and configuration of data input elements
    - Interactive web-based data entry with centralized abstraction
    - Database integrity checks, security, and encrypted data transmission
  - Compliance with 21 CFR Part 11
- Biorepository
  - Use of “best practices” in biobanking to ensure the highest quality specimens
  - Development of SOPs in compliance with Good Laboratory Practice guidelines
    - Biobanking CAP accreditation program
  - Sample tracking: REDCap database linked to OnCore sample database

HCV TARGET

HCV-TARGET Enrollment Summary

Major Characteristics	N=1150
Male	59%
Age 18-64	90%
Age ≥ 65	7%
White	73%
Black	20%
Asian	2%
Hispanic	7%
Geno 1a	55%
Geno 1b	20%
Geno 2, 3, 4	1%
Cirrhosis	29%

HCV TARGET

HCV-TARGET and the FDA Opportunities

- Enable high quality, more efficient and well powered phase IV (FDA-mandated post-marketing requirements) clinical studies
  - Examples of observational registries to address a PMR/PMC
    - HBV: Truvada maternal and fetal outcomes
    - Gaucher: Elelyso (recombinant Human G) long-term safety and efficacy
- Inform benefit/risk of new therapies in a pragmatic setting
- Inform the design of clinical trials for next generation HCV drugs and current approved drugs
- Serve as a platform for biomarker, bioinformatics, and quantitative pharmacology methods and tools to explore unanticipated clinical responses and generate hypothesis

HCV TARGET

Benefit of HCV-TARGET
Summary

- Academic, Industry, and NIH partnership
  - Translational research opportunities
  - Explore FDA link
- Leverages existing national research infrastructure
  - Biorepository, design and analysis, regulatory, etc
- Standardizes data acquisition using CTSA open source database (REDCaP) and sample collection
- Engages community-based providers geographically related to academic centers
  - Unique T2-T4 research and educational opportunities
- Potential for rapid recruitment of patients

HCV TARGET